NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Nov 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Clinical Trials (5)
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Started Jun 2018
6 enrolled
Metastatic Urothelial Cell Cancer
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Started Apr 2018
23 enrolled
Relapsed/Refractory RhabdomyosarcomaNon-rhabdomyosarcoma Soft Tissue SarcomaEwing Sarcoma
A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
Started Mar 2018
200 enrolled
Breast Neoplasms
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Started Aug 2017
446 enrolled
Breast Cancer
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Started Mar 2017
90 enrolled
Breast Cancer
Loss of Exclusivity
LOE Date
Jul 8, 2027
16 months away
Patent Expiry
Jul 8, 2027
Exclusivity Expiry
Mar 13, 2026
Patent Records (2)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| RE46965 | Jan 8, 2027 | Product | — |
| RE46965*PED | Jul 8, 2027 | — |
Company
E
Eisai
China - Liaoning